PR Newswire: news distribution, targeting and monitoring
 

CVS Caremark Study Finds Value Based Insurance Designs Can Increase Adherence in Diabetes Patients

 
 

Benefit Design Plans that Offer Participants Financial Incentives Result in Significant improvements to medication adherence

WOONSOCKET, R.I., Feb. 16 /PRNewswire/ -- A study by CVS Caremark (NYSE: CVS), published this week in the American Journal of Pharmacy Benefits, finds that insurance benefit designs that reduce the cost of medications for plan participants result in patients being more likely to start and stay on their medication therapy.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO )

The study compared more than 20,000 plan participants in value-based insurance design (VBID) plans to more than 190,000 participants of similar age and gender breakdowns in standard three-tier plans. The study concluded initiation and adherence rates for both insulin and oral diabetes medicines among participants in value-based plans were significantly higher.  

"There have been discussions around the impact of price and affordability on patients' ability and willingness to start and stay on their medications and this research adds to that body of knowledge. We took a look at one disease state – diabetes – and showed how cost impacts a patient's prescription initiation and adherence rates," said Troyen A. Brennan, M.D., M.P.H., Executive Vice President and Chief Medical Officer, CVS Caremark.  "This research is important as we seek to educate the public and patients that adherence can be the most cost effective intervention in health care."

In the VBID plans studied, generic co-pays were reduced from $15 to zero, preferred brands dropped to between $10 and $15 from $30, and non-preferred brands remained at $35 co-pay, compared with standard plans which had no changes in co-pays during the study period. Participants in VBID plans had higher prescription initiation rates (2.3% versus 1.6% on the total study population) and lower discontinuation rates (16% versus 24.3%).

This study is part of a broader research effort by CVS Caremark to learn more about why patients do not take prescriptions that are prescribed, or drop the medications in the middle of therapy. The research includes continuing internal analysis of CVS Caremark clients and an external partnership with Harvard and Brigham & Women's Hospital.  Separately, a recent study by the New England Healthcare Institute found that not taking medications as prescribed leads to poorer health, more frequent hospitalization, a higher risk of death and as much as $290 billion annually in increased medical costs.

The research findings will be used to develop programs that aim to improve patient education about the importance of adherence, and communications for timely interventions with patients that include face-to-face first fill counseling; IVR and Web refill reminders, renewals and pick-up prompts; and outreach calls to potentially non-adherent patients from their local CVS pharmacist.

"As the health care debate continues, one thing is clear: We all have to find ways to make health care more affordable," Brennan said. "Our passion and expertise is to help our clients receive the best pharmacy care available, and that can be achieved by focusing on adherence to impact the health of our customers and help take costs out of the health care system," Brennan said.

About CVS Caremark

CVS Caremark is the largest pharmacy health care provider in the United States.  Through our integrated offerings across the entire spectrum of pharmacy care, we are uniquely positioned to provide greater access, to engage plan participants in behaviors that improve their health and to lower overall health care costs for plan sponsors and participants. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics. We are also a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefit managers (PBMs), we provide access to a network of approximately 60,000 pharmacies, including approximately 7,000 CVS/pharmacy stores that provide unparalleled service and capabilities. Our clinical expertise includes one of the industry's most comprehensive disease management programs. General information about CVS Caremark is available through the Company's Web site at http://info.cvscaremark.com

Media Contact:


Christine Cramer

Jon Tashjian

CVS Caremark

Weber Shandwick

(401) 770-3317

(617) 520-7118

ckcramer@cvs.com

jtashjian@webershandwick.com


SOURCE CVS Caremark

Back to top

RELATED LINKS
http://info.cvscaremark.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

Featured Video

 
  • Print
  • Email
  •   RSS
  • Share it  
  • Blog it  
  • Blog Search  

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Free Investing Newsletter from Investor Uprising!

Learn to navigate the world's financial system and profit from leading companies.  

Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".

Advanced Search
Search
  
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire